Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes | Zendy

Elin Nyman | Zendy; Yvonne Wesseling-Rozendaal | Zendy; Gabriel Helmlinger | Zendy; Bengt Hamrén | Zendy; Maria C. Kjellsson | Zendy; Peter Strålfors | Zendy; N.A.W. van Riel | Zendy; Peter Gennemark | Zendy; Gunnar Cedersund | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes

Author(s) -

Elin Nyman,

Yvonne Wesseling-Rozendaal,

Gabriel Helmlinger,

Bengt Hamrén,

Maria C. Kjellsson,

Peter Strålfors,

N.A.W. van Riel,

Peter Gennemark,

Gunnar Cedersund

Publication year - 2016

Publication title -

interface focus

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.1

H-Index - 49

eISSN - 2042-8901

pISSN - 2042-8898

DOI - 10.1098/rsfs.2015.0075

Subject(s) - computer science , data science , systems biology , systems pharmacology , risk analysis (engineering) , bioinformatics , medicine , drug , biology , pharmacology

We are currently in the middle of a major shift in biomedical research: unprecedented and rapidly growing amounts of data may be obtained today, from in vitro, in vivo and clinical studies, at molecular, physiological and clinical levels. To make use of these large-scale, multi-level datasets, corresponding multi-level mathematical models are needed, i.e. models that simultaneously capture multiple layers of the biological, physiological and disease-level organization (also referred to as quantitative systems pharmacology-QSP-models). However, today's multi-level models are not yet embedded in end-usage applications, neither in drug research and development nor in the clinic. Given the expectations and claims made historically, this seemingly slow adoption may seem surprising. Therefore, we herein consider a specific example-type 2 diabetes-and critically review the current status and identify key remaining steps for these models to become mainstream in the future. This overview reveals how, today, we may use models to ask scientific questions concerning, e.g., the cellular origin of insulin resistance, and how this translates to the whole-body level and short-term meal responses. However, before these multi-level models can become truly useful, they need to be linked with the capabilities of other important existing models, in order to make them 'personalized' (e.g. specific to certain patient phenotypes) and capable of describing long-term disease progression. To be useful in drug development, it is also critical that the developed models and their underlying data and assumptions are easily accessible. For clinical end-usage, in addition, model links to decision-support systems combined with the engagement of other disciplines are needed to create user-friendly and cost-efficient software packages.

Funding agencies: Swedish Research Council; Swedish Diabetes Foundation; Linkoping Initiative within Life Science Technologies; CENIIT; Ostergotland County Council; EU [FP7-HEALTH-305707]; AstraZeneca

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research